WO2002087603A1 - Immunostimulants - Google Patents
Immunostimulants Download PDFInfo
- Publication number
- WO2002087603A1 WO2002087603A1 PCT/JP2002/004205 JP0204205W WO02087603A1 WO 2002087603 A1 WO2002087603 A1 WO 2002087603A1 JP 0204205 W JP0204205 W JP 0204205W WO 02087603 A1 WO02087603 A1 WO 02087603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mushroom
- glucan
- ultrafine particle
- agent
- extract
- Prior art date
Links
- 230000000091 immunopotentiator Effects 0.000 title abstract 2
- 239000000284 extract Substances 0.000 claims abstract description 154
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 138
- 238000000034 method Methods 0.000 claims abstract description 52
- 235000013305 food Nutrition 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 26
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 22
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 12
- 229960005475 antiinfective agent Drugs 0.000 claims abstract description 11
- 239000004599 antimicrobial Substances 0.000 claims abstract description 11
- 239000003443 antiviral agent Substances 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 10
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 7
- 239000006286 aqueous extract Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 239000011882 ultra-fine particle Substances 0.000 claims description 150
- 229920001503 Glucan Polymers 0.000 claims description 137
- 239000002245 particle Substances 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 77
- 239000007864 aqueous solution Substances 0.000 claims description 63
- 239000003814 drug Substances 0.000 claims description 41
- 239000003995 emulsifying agent Substances 0.000 claims description 37
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 36
- 230000003308 immunostimulating effect Effects 0.000 claims description 36
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 239000002270 dispersing agent Substances 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 27
- 239000002955 immunomodulating agent Substances 0.000 claims description 23
- 239000003022 immunostimulating agent Substances 0.000 claims description 23
- 235000000346 sugar Nutrition 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 229940121354 immunomodulator Drugs 0.000 claims description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 229960001438 immunostimulant agent Drugs 0.000 claims description 20
- 239000000787 lecithin Substances 0.000 claims description 20
- 235000010445 lecithin Nutrition 0.000 claims description 20
- 229940067606 lecithin Drugs 0.000 claims description 20
- 206010010774 Constipation Diseases 0.000 claims description 18
- 206010012735 Diarrhoea Diseases 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000003472 antidiabetic agent Substances 0.000 claims description 13
- 230000002584 immunomodulator Effects 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 230000003266 anti-allergic effect Effects 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- 239000000693 micelle Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 229940125708 antidiabetic agent Drugs 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 229940124568 digestive agent Drugs 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 240000000599 Lentinula edodes Species 0.000 abstract description 49
- 239000004480 active ingredient Substances 0.000 abstract description 20
- 239000000043 antiallergic agent Substances 0.000 abstract description 6
- 208000010643 digestive system disease Diseases 0.000 abstract description 5
- 239000000843 powder Substances 0.000 abstract description 5
- -1 antidiabetics Substances 0.000 abstract description 4
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 42
- 235000001715 Lentinula edodes Nutrition 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 25
- 239000000047 product Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 230000004614 tumor growth Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 235000013402 health food Nutrition 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 210000004347 intestinal mucosa Anatomy 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 238000012353 t test Methods 0.000 description 8
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 230000036737 immune function Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 230000005951 type IV hypersensitivity Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000006268 Sarcoma 180 Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000001142 back Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000001497 healthy food Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000035874 Excoriation Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 240000001080 Grifola frondosa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000790210 Crepidotus variabilis Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241001313710 Dictyophora indusiata Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000006499 Flammulina velutipes Species 0.000 description 1
- 235000016640 Flammulina velutipes Nutrition 0.000 description 1
- 241000123330 Fomes fomentarius Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 244000097863 Grifola umbellata Species 0.000 description 1
- 235000002897 Grifola umbellata Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 241000218554 Lyophyllum Species 0.000 description 1
- 244000103635 Lyophyllum ulmarium Species 0.000 description 1
- 235000015934 Lyophyllum ulmarium Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000215599 Peziza vesiculosa Species 0.000 description 1
- 244000168667 Pholiota nameko Species 0.000 description 1
- 235000014528 Pholiota nameko Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000002548 cytokinetic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/271—Curdlan; beta-1-3 glucan; Polysaccharides produced by agrobacterium or alcaligenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
- A23L31/15—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an ultrafine particle of a novel mushroom-derived component, such as an ultrafine particle of a new mushroom extract (preferably, an ultrafine particle of a component obtained by water extraction of a mushroom).
- a novel mushroom-derived component such as an ultrafine particle of a new mushroom extract (preferably, an ultrafine particle of a component obtained by water extraction of a mushroom).
- the immunostimulant Z immunomodulator of the present invention is used in various forms such as pharmaceuticals (pharmaceutical compositions), foods and drinks (healthy foods, functional foods, etc.), and particularly activates or regulates the immune function to treat diseases.
- the present invention relates to tumors, infectious diseases, viral diseases, autoimmune diseases, diabetes, allergic diseases, digestive diseases (irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), constipation, diarrhea).
- it also includes use in pharmaceutical production.
- Background art Since mushrooms or their components contain various medicinal ingredients, health foods containing powdered and processed forms of certain mushrooms and hot-water extracted products are known. However, conventionally known products do not effectively utilize the various components.
- An object of the present invention is to provide a food or drink (healthy food, functional food, etc.) or a pharmaceutical (pharmaceutical composition) effectively utilizing various components of mushrooms or similar materials by a simple preparation means, particularly a medicinal component. ). Disclosure of the invention
- the present inventors have conducted intensive studies on the use of various components in conventional products in order to solve the above-mentioned problems, and as a result, these various components formed in the animal body are not sufficiently absorbed, and as a result, they are expected in the body. Has not been used. Furthermore, as a result of further study, it was found that a mushroom-derived component, particularly a water extract of mushrooms, preferably a hot water extract, in which the particle size was reduced to ultrafine particles (ultrafine particles) was prepared.
- the present invention has been completed based on the above various findings.
- it stimulates and activates mucosal immunity (to stimulate systemic immunity) by absorption from the mucous membrane (particularly the small intestine) in the body, and as a result, has an antitumor effect and treats infections caused by viruses and bacteria such as AIDS.
- the improvement effect is expected. Therefore, this ultrafine particle is an immunostimulant / immunomodulator. It can be used as a moderator, and is expected to be used in the form of pharmaceutical compositions, foods and drinks (health foods, etc.)
- the present invention provides, as one form, a micronized substance characterized by ultrafine particles of a mushroom-derived component and a component selected from 8-glucan, for example, a mushroom-derived component or / 3-glucan. Ultra fine particles characterized by being made into ultra fine particles.
- a micronized substance characterized by ultrafine particles of a mushroom-derived component and a component selected from 8-glucan, for example, a mushroom-derived component or / 3-glucan.
- Ultra fine particles characterized by being made into ultra fine particles.
- there is [3] -glucan see International Application Publication No. WO01 / 85141
- the present invention is based on mushroom-derived components and] 3-glucan.
- muscle-derived component is a general term for components produced by mushrooms.
- the mushroom-derived component is not particularly limited as long as it is a component contained in the mushroom or a component that produces the mushroom.
- it may include a plurality of components contained in mushrooms, such as a mushroom extract or a mushroom water extract.
- the [3-glucan] used in the present invention may be a mushroom-derived component as described above, or may be] -glucan that is not included in the mushroom-derived component.
- 3-glucan examples include yeast-derived components (such as beer yeast), fungal-derived components, bacterial-derived components, and plant-derived components.
- the mushroom extract is preferably an extract of water (including an extract of water, hot water, a solution containing water, etc.) in that the present invention can obtain a large amount of active ingredients.
- the water extract of mushrooms may be any component that has been extracted from mushrooms with water or contains this component.
- an extract obtained by extracting mushrooms with water may be filtered with filter paper (the type of filter paper used is not particularly limited.
- Such an aqueous extract can then be subjected to a micronization step in the present invention.
- the aqueous solution containing these components is referred to as a mushroom aqueous extract-containing aqueous solution.
- These components do not necessarily need to be completely dissolved in the aqueous solution.
- a / 3-glucan extract () 3-glucan extract component
- a / 3-glucan extract can be used as in the case of the mushroom extract described above.
- a conventionally known extraction method for example, an extraction method using water or hot water (see Biol. Pharm. Bull., 23 (7), 866, 2000) or enzyme treatment (See JP-A-5-268905 and JP-A-10-287584).
- 3-glucan extract is referred to as an aqueous solution containing / 3-glucan extract.
- the component When ultrafine particles of the component selected from the mushroom-derived component and / 3-glucan, the component preferably forms an aggregate in an aqueous solution. Further, it is more preferable that the aggregate has a particle size of at least 50 m (5011 or more).
- the average particle diameter of the ultrafine particles of the present invention is preferably 10 m or less, more preferably lm or less, and more preferably 0 m or less, when the ultrafine particles are dispersed in water and measured. It has an average particle size of about 0.1 to 1. This average particle size can be easily obtained by a particle size distribution meter.
- An ultrafine particle obtained from a mushroom-derived component and a component selected from 3-glucan preferably in an aqueous solution, in a state treated with a dispersant or in a dispersed state.
- An ultrafine particle containing particles having an average particle size of 1 or less which can be obtained by mixing a dispersant with an aqueous solution containing a component selected from mushroom-derived components and j3-glucan.
- the ultrafine particle according to the above (1) or (2) which contains particles having an average particle diameter of 1 m or less, which can be obtained during the pulverization treatment.
- the aqueous solution containing a component selected from a mushroom-derived component and a / 3-glucan is a mushroom extract-containing aqueous solution obtained by filtering a mushroom water or hot water extract with a filter paper or the like.
- the 3-glucan may be a component contained in the mushroom-derived component or a component not contained therein.
- the aqueous solution containing a component selected from mushroom-derived components and) 3-glucan is not particularly limited, and may be any aqueous solution containing a mushroom-derived component and a component selected from / 3-glucan.
- the components need not be completely dissolved in the aqueous solution.
- an aqueous solution containing a mushroom extract or an aqueous extract containing a mushroom water extract may be used, or a culture solution containing a mushroom mycelium culture product may be used.
- a solution containing at least a component derived from water and a component selected from / 3-glucan may be used.
- aqueous solution containing) 3-glucan component
- Any aqueous solution containing] 3-glucan may be used.
- 3-Glucan does not need to be completely dissolved in the aqueous solution.
- An aqueous solution containing glucan can be used.
- this ⁇ -glucan may be a mushroom-derived component or may not be included in the mushroom-derived component.
- the above-mentioned 3-glucan extract component can be used.
- the weight ratio of the total dispersing agent to the total sugar (total amount of sugar) 1 contained in the aqueous solution containing the component selected from the mushroom-derived component and the 3-glucan is preferably large. In all, 100 (100 or less), more preferably 10 or less, and even more preferably about 0.05 to 5 can be mixed.
- the content of mushroom-derived components and components selected from 3-glucan contained in the aqueous solution there are no particular restrictions on the content of mushroom-derived components and components selected from 3-glucan contained in the aqueous solution.
- the total sugar concentration is as high as S OmgZm l (5 OmgZm 1 or less). ), more preferably such that 0. 5 to 50 mg / m 1 of about range, it is setting the content of the component selected from the mushroom-derived component and / 3 Group Cikarang contained in the aqueous solution.
- the type of the dispersant is not particularly limited, and examples thereof include a surfactant, a polymer, a saccharide, a sugar alcohol, glyceride, an acid, a base, and a salt.
- a surfactant emulsifiers represented by surfactants are preferred, and lecithin can be employed as more preferred.
- the ultrafine particles of the present invention can be obtained in the form of micelles using an emulsifier and used.
- the pulverization method is not particularly limited, but a wet pulverization method is preferable, and examples thereof include a high-pressure emulsifier, a medium mill, and ultrasonic waves.
- a high-pressure emulsifier ultrafine particles (ultrafine particles) of 1 / zm or less can be prepared as described above.
- the emulsification pressure used at this time is preferably 300 kgf Zcm 2 or more, more preferably 500 kgf / cm 2 , and still more preferably 800 kg fcm 2 or more. Can be reduced.
- Such an ultrafine particle is preferably a mushroom water or hot water extract, or] 3-glucan extract, which is obtained by filtering a mushroom extract or 3-g It can be obtained by mixing a dispersing agent with an aqueous solution containing a lucan extract, and preferably stirring the mixture. In this way, an ultrafine particle containing particles having an average particle diameter of 10 / zm or less can be obtained.
- an aqueous solution containing the extract of mushrooms an aqueous solution containing aggregates obtained by filtering the mushroom water or hot water extract with a filter paper and then concentrating and / or cooling the same can be used.
- an aqueous solution that gives the above-mentioned aggregates when it is concentrated and / or cooled can be used as it is after filtration.
- the same treatment as above can be prepared by using the same treatment for / 3-glucan and used.
- an immunostimulant or immunomodulator in the form of an aqueous solution or dispersion of the ultrafine particles, for example, an aqueous solution or dispersion in which the active ingredient is ultrafine
- the above-mentioned mushroom extract is treated with a dispersing agent, etc.), and is preferably in the form of micelle. Among them, it is convenient to use a mushroom extract or a product treated with a dispersing agent of) 3-glucan.
- the ultrafine particles in various forms are also included in the ultrafine particles of the present invention.
- the hot water extract described above for example, a mushroom hot water extract, is preferably subjected to hot water extraction after pulverizing mushrooms from the viewpoint of efficient extraction of an active ingredient.
- the ultrafine particles can be absorbed from the mucous membrane of the small intestine of an animal, particularly a human, and as a result, can exert an immunostimulating effect or an immunomodulating effect.
- an immunostimulating agent and / or an immunomodulating agent characterized by containing the ultrafine particle of any one of the above.
- the present invention resides in a pharmaceutical composition (drug; pharmaceutical) characterized by containing any of the ultrafine particles described above.
- a pharmaceutically acceptable carrier e.g., a pharmaceutically acceptable styrene, a pharmaceutically acceptable styrene, a pharmaceutically acceptable styrene, a pharmaceutically acceptable styrene, a pharmaceutically acceptable styrene, a pharmaceutically acceptable styl, a sulfate, a sulfate, a sulfate, a stiol, g., a stiol, a stylitol, a stylitol, a stylitol, a stylitol, a styrene, a styrene, a styrene, a styrene, a styrene, styrene,
- the immunostimulant immunomodulator can also be used in the form of a food or drink.
- specific examples of the drug include an antitumor agent, an anti-infective agent, an antiviral agent, an anti-immune disease agent, Antidiabetic, antiallergic and antidigestive (irritable bowel syndrome ( IBS), inflammatory bowel disease (IBD), therapeutic agents for constipation, diarrhea, etc.).
- Another aspect of the present invention resides in a food or drink characterized by containing the ultrafine particle of any one of the above (the ultrafine particle of the present invention).
- the content of the ultrafine particles is not limited, the ultrafine particles in foods and drinks such as health foods are about 0.01 to 80% by weight, more preferably 0.05 to 0.5% by weight in terms of total sugars. It is desirable to contain about 20% by weight.
- Food and drink is a combination of food and beverage.
- the food and drink of the present invention can be used for health foods, functional foods, health drinks, functional drinks, and the like.
- cancer diseases bacterial infection diseases, virus infection diseases, autoimmune diseases, diabetes, allergic diseases, digestive diseases (irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), constipation, diarrhea, etc.) It is suitable for patients with diseases.
- the present invention provides, as yet another form, an ultrafine particle-containing composition characterized by containing an aqueous solution in which the ultrafine particle of the present invention is dispersed, that is, an ultrafine particle. It also exists in aqueous solutions (dispersions, etc.).
- composition can be used for a pharmaceutical composition (pharmaceutical) as described above.
- the composition may contain a pharmaceutically acceptable carrier or bulking agent.
- the composition can be contained in food or drink in an amount of 0.05 to 5% by weight in terms of total sugars.
- the food or drink of the present invention includes health foods, functional foods, health drinks, functional drinks, and the like. It can be used for In particular, cancer diseases, bacterial infectious diseases, viral infectious diseases, autoimmune diseases, diabetes, allergic diseases, gastrointestinal diseases (irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), constipation, diarrhea, etc.) It is suitable for patients with diseases.
- the sugar is about 1 to 200 mg, more preferably about 100 to 100 mg per 100 g of the composition, and a dispersant is preferable. About 1 to 200 mg, more preferably about 10 to: L about 100 mg I can do it.
- the composition containing ultrafine particles is not particularly limited as long as it is a composition containing an ultrafine particle such as a mushroom-derived component or / 3-glucan.
- it is an aqueous solution containing a mushroom-derived component or an ultrafine particle of / 3-glucan and a dispersant, and more preferably, an ultrafine particle prepared by mixing a dispersant with an aqueous solution containing the component. And an aqueous solution in which the ultrafine particles thereof are dispersed (converted).
- a method for producing an ultrafine particle which comprises subjecting a component selected from a mushroom-derived component and 3-glucan, that is, a mushroom-derived component or 3-glucan to an ultrafine particle-forming step.
- a method for example, a method for producing an ultrafine particle by subjecting a mushroom to a water extraction step and then subjecting the obtained water extract to an ultrafine particle step.
- the dispersant is mixed with the aqueous extract-containing aqueous solution of the obtained mushroom, and preferably the average particle size is 10 m by stirring.
- An ultrafine particle containing the following particles can be produced.
- an aqueous solution containing aggregates obtained by filtering mushroom water or a hot water extract with a filter paper or the like, and then concentrating and / or cooling the same may be used as the extract-containing aqueous solution as described above. It is also possible to use an aqueous solution which gives the above-mentioned aggregates when it is concentrated and Z or cooled after being filtered, in the state after filtration. / 3—Glucan can be produced in the same way.
- a dispersing agent is mixed with an aqueous solution containing a mushroom-derived component and a component selected from 8-glucan as described above, for example, a particle having an average particle size of 10 / zm or less.
- the step of preparing ultrafine particles includes a step of preparing particles having an average particle size of 1 m or less by a fine pulverization treatment, for example, a high-pressure emulsifier treatment process. be able to.
- an ultrafine particle having preferably an immunostimulatory activity and / or an immunomodulatory activity
- the present invention further provides, as another form, a product selected from mushroom-derived components and 3-glucan.
- the present invention also provides a method for producing an ultrafine particle-containing composition, which is characterized in that a component, for example, a mushroom-derived component is subjected to an ultrafine particle forming step.
- This method can be carried out according to the method for producing an ultrafine particle.
- a process of preparing a particle having an average particle diameter of 10; m or less by mixing a dispersing agent with an aqueous solution containing a component selected from mushroom-derived components and 3-glucan A step of preparing particles having an average particle size of lm or less by pulverization treatment, for example, treatment with a high-pressure emulsifier can be employed.
- the water or hot water extract obtained after subjecting the mushroom to the extraction step with water or hot water can be used as a component selected from the mushroom-derived component and the 3 glucan.
- an aqueous solution containing a mushroom extract or a mushroom extract obtained by filtering a mushroom water or hot water extract with a filter paper or the like can be used.
- a / 3-glucan extract can be similarly prepared.
- the present invention resides in an immunostimulatory method or an immunoregulatory method characterized by ingesting or administering the above-described ultrafine particles of the present invention into a living body, and comprises a tumor, an infectious disease, and a viral disease.
- an immunostimulatory method or an immunoregulatory method characterized by ingesting or administering the above-described ultrafine particles of the present invention into a living body, and comprises a tumor, an infectious disease, and a viral disease.
- autoimmune diseases diabetes, allergic diseases, digestive diseases (irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), constipation, diarrhea, etc.)
- IBS irritable bowel syndrome
- IBD inflammatory bowel diseases
- constipation constipation, diarrhea, etc.
- the above-mentioned ingestion or administration forms include the above-mentioned immunostimulants, immunomodulators, etc .; or the above anti-tumor agents, anti-infective agents, anti-viral agents, anti-autoimmune disease agents, anti-diabetic agents, anti-allergic agents, anti-digestion agents
- Drugs for organ disorders can be employed.
- it can be preferably used in the form of the pharmaceutical composition, food or drink.
- the present invention further provides, as yet another form, the use of the novel ultrafine particle as the immunostimulating agent or the immunomodulator; or the use of the ultrafine particle as the antitumor agent, anti-infective agent, antiviral agent, Anti-autoimmune drugs, anti-diabetic drugs, anti-allergic drugs, anti-digestive drugs
- Immunostimulants and immunomodulators or anti-tumor agents, anti-infectives, anti-virals, anti-autoimmune agents, anti-diabetic agents, anti-allergic agents, anti-digestive disorders (irritable bowel syndrome (IBS) , Inflammatory bowel disease (IBD), therapeutic agents for constipation, diarrhea, etc.) are as described above, and as described above, the form of the pharmaceutical composition or the form used for food and drink is used. Preferred examples can be given. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 shows the particle size distributions of Shiitake extract and micellarized Shiitake extract in Example 1.
- micellar extract of Example 1 In the emulsifier treatment of micellar extract of Example 1 [micellarization], the particle size distribution of the extract of shiitake mushroom (left figure: 11a) and the micellar extract of shiitake mushroom (the present invention) (right figure: 11b) were determined. It is illustrated.
- the horizontal axis represents the particle diameter (m)
- the vertical axis (left) represents the particle frequency (%) for the bar graph
- the vertical axis (right) represents the particle frequency accumulation (%) for the curve. .
- FIG. 2 shows the particle size distribution of] 3-glucan solution and micellarized] 8-glucan in Example 2.
- the ⁇ -glucan solution (left figure: 2-a) and the micellized form] 3-glucan (product of the present invention) (right figure: 2-b) 1 is a diagram illustrating the particle size distribution.
- the horizontal axis represents the particle size ( ⁇ m)
- the vertical axis (left) represents the particle frequency (%) for the bar graph
- the vertical axis (right) represents the particle frequency accumulation for the curve. (%), Respectively.
- the type of mushroom is not particularly limited. There is no particular restriction on the position used for extraction. What can be provided for edible use can be used. Representative examples are as follows, but are not limited thereto.
- mushrooms refer to fungi that can form fruiting bodies.
- Pleurotus ostreatus (oyster mushroom)
- Flamniul ina velutipes (Enokitake)
- Fomi tops is p inicola
- the active ingredient in the present invention is an ultrafine particle of a component extracted with water (hot water or the like) among components excluding water.
- j3-glucan there is no particular limitation on j3-glucan, and mushroom-derived components, yeast-derived components, fungal-derived components, bacterial-derived components, plant-derived components, and the like can be employed.
- an extract of mushroom-derived components or / 3-glucan there is no particular difficulty in obtaining an extract of mushroom-derived components or / 3-glucan.
- it may be extracted with water such as hot water using mushrooms.
- water such as hot water using mushrooms.
- the ground product is subjected to a hot water extraction process, the extraction process is easy.
- hot water a temperature of about 60 to 100 is adopted.
- the filtrate obtained by filtration through a filter paper the type of filter paper to be used is not particularly limited and can be selected as needed.
- a solution containing aggregates after concentration, cooling, or the like is also included in the extract of the present invention.
- the extract may be any component (not necessarily completely dissolved) contained in water in the extraction step with water (hot water or the like).
- the filtrate includes a filtrate filtered through a filter paper or the like after the extraction step, and fine particle components (aggregates and the like) precipitated from the extract by concentration, cooling, and the like.
- an ultrafine particle having an immunostimulating activity or an immunomodulating activity can be produced.
- Extracted from mushrooms with hot water, etc. Extracted from mushrooms with hot water, etc. (extract), for example, after the extraction process, after hot filtration (celite filtration, etc.), and after cooling or concentrating and cooling, average particle size of 100 xm or more Are precipitated.
- This aggregate is considered to be a product formed by aggregation of a polysaccharide such as 3-glucan or a peptide glucan in the extracted extract.
- the filtrate obtained is observed to be a suspension in which fine particles are dispersed in the filtrate. .
- the particle diameter of the particles was measured, it was confirmed that the particles were aggregates having a median diameter of about 250 im, and that the components of the particles were) 3-glucan, peptide glucan, and the like.
- the active ingredient in the extract When taken orally in such a state (an extract containing aggregates having an average particle size of 100 / zm or more), the active ingredient in the extract is not efficiently absorbed from the intestinal mucosa, It is not used effectively by living organisms. According to the microparticulate according to the present invention, the active ingredient in such an extract can be efficiently absorbed from the intestinal mucosa, and an immune reaction can be induced in the lamina intestinal.
- a dispersing agent etc.
- the precipitated aggregate can be dispersed using a dispersing agent for a solution containing the active ingredient of the mushroom extract extract contained therein. Either embed the active ingredient of the mushroom extract contained in microcapsules, or disperse the precipitated aggregates with a dispersant This can be achieved by embedding in microcapsules or the like.
- the presence or absence of immunostimulatory activity should be easily determined by measuring the antitumor activity, NK (Natural Killer) activity, delayed-type hypersensitivity reaction, intracellular and extracellular cytokinetic measurements, antibody production, etc. Can be.
- ultrafine particles can be formed using a stirrer or a homogenizer, for example, using an appropriate dispersant. Further, ultrafine particles can be formed by a fine pulverization treatment using a high-pressure emulsifier, a medium mill, or ultrasonic waves.
- any dispersing agent having a property of being dispersed in a liquid may be used, and there is no particular limitation.
- those used as emulsifiers are preferred.
- More preferably, edible emulsifiers are used.
- lecithin, lysolecithin, bile acids and the like can be used.
- dispersing using an emulsifier is particularly described as micelle formation, but the present invention is not limited to this, and dispersants other than the emulsifier are used. Micelle formation is also included in the present invention.
- the micronization step in the present invention may be carried out in at least one of a step for obtaining an active ingredient, for example, a pre-step, a post-step, and a simultaneous step such as an extraction step.
- a step for obtaining an active ingredient for example, a pre-step, a post-step, and a simultaneous step such as an extraction step.
- the ultrafine particle of the present invention is measured by dispersing the ultrafine particle in water, it is preferably 10 im or less, more preferably 1 m or less, and still more preferably 0.01 to 1 ⁇ m. Ultra fine particles having an average particle size of about ⁇ can be used.
- a dispersant-treated liquid (dispersed liquid), especially in the form of micelles treated with an emulsifier, is preferred in terms of digestion and absorption, but is converted to dry ultrafine particles
- the body can also be used as an immunostimulant / immunomodulator.
- the method for measuring ultrafine particles can be performed using a method for measuring ordinary particles, particularly particles in a dispersed state. For example, it can be measured by a laser diffraction / confusion type particle size distribution measuring method using a particle size distribution meter.
- the micronized product of the present invention is an immunostimulant It can be used as an active ingredient of a nodal agent (immunostimulant Z immunomodulator of the present invention).
- Carriers and extenders (or diluents) that can be used for the pharmaceutical composition, food or drink of the present invention can also be used. Specifically, it can be used as a pharmaceutical composition or a food or drink (health food or the like).
- an immunostimulatory or immunomodulatory effect can be easily confirmed by measuring, for example, antitumor activity, NK activity, delayed-type hypersensitivity reaction, intracellular and extracellular cytoin, and antibody production. .
- the pharmaceutical composition (drug) of the present invention contains the above micronized product, preferably a dispersant-treated solution (dispersed solution), particularly preferably a micellar component using an emulsifier as an active ingredient.
- a dispersant-treated solution preferably a micellar component using an emulsifier as an active ingredient.
- it is a drug that activates or regulates systemic immunity and can be used for treating, improving, preventing progress of diseases associated with immune abnormalities, and preventing other diseases.
- diseases associated with immune abnormalities for example, anti-tumor, anti-infective, anti-viral, anti-autoimmune, anti-diabetic, anti-allergic, anti-gastrointestinal (irritable bowel syndrome (IBS), inflammatory bowel disease ( IBD), therapeutic agents for constipation, diarrhea, etc.
- IBS irritable bowel syndrome
- IBD inflammatory bowel disease
- the subject to whom this drug is applied is an animal, especially a human, who seeks to activate or modulate immunity, especially systemic immunity.
- One of the features of the drug of the present invention is that it shows an excellent effect even by oral administration, and it is possible to use an extract mixture of mushroom-derived components and 3-glucan, for example, mushrooms, particularly edible mushrooms, etc. It can be mentioned that it is excellent. Therefore, there is no particular limitation on the administration form. Oral administration, parenteral administration (subcutaneous, intramuscular administration, nasal administration, aerosol administration, etc.) Various administration forms are available, and it is wide and simple for patients who require immunostimulatory action and Z or immunomodulatory action. It can be applied to Because of its safety and suitability for oral administration, it can be used in the form of health foods, functional foods, health drinks, functional drinks, etc. as described below to prevent and improve such diseases. .
- the present invention can be used, for example, in combination or combination with other drug components (pharmaceutically active substances). Any substance which contains the desired pharmacological activity (immunostimulatory activity or immunomodulatory activity) is included in the agent of the present invention.
- compositions adjuvants may also contain various pharmacologically acceptable substances for pharmaceuticals (as adjuvants, etc.).
- Pharmaceutical substances can be appropriately selected according to the dosage form of the pharmaceutical preparation.
- examples include excipients, diluents, additives, disintegrants, binders, coating agents, lubricants, lubricants, lubricants, and flavors.
- specific examples of substances for preparation include magnesium carbonate, titanium dioxide, lactose, mannitol and other saccharides, talc, milk protein, gelatin, starch, cellulose and derivatives thereof, animal and vegetable oils, polyethylene glycol, and solvents.
- the drug of the present invention can be in the form of various pharmaceutical preparations known or to be developed as described above, for example, oral administration, intraperitoneal administration It can be prepared into various administration forms such as transdermal administration and inhalation administration. In order to prepare the drug of the present invention in the form of these various pharmaceutical preparations, known or future-developed methods can be appropriately adopted.
- compositions include, for example, suitable solid or liquid forms, such as granules, powders, coated tablets, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops.
- suitable solid or liquid forms such as granules, powders, coated tablets, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops.
- suitable solid or liquid forms such as granules, powders, coated tablets, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops.
- suitable solid or liquid forms such as granules, powders, coated tablets, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops.
- Agents, solutions for injection, and agents for prolonging the release of the active substance include, for example, suitable solid or liquid forms, such as granul
- the drug of the present invention in the above-mentioned preparation form should contain an effective amount of the above-mentioned components to exhibit a drug effect.
- the dose of the drug of the present invention is appropriately selected depending on the type and degree of the disease, the form of the preparation, and the like.
- a micronized form of the active ingredient per patient per day expressed in terms of total sugar, is preferably about lmg to 50 g, more preferably about 10 mg to 10 g, and still more preferably about 50 mg.
- About 5 mg to 5 g can be administered.
- the dose can be further increased.
- the number and timing of administration can be once every few days or once a day, but usually it is administered several times a day, for example, 2 to 4 times, before, between meals and after meals Is done. Preferably, it is administered before a meal.
- intravenous administration about 10 to 1/100 of the administration compared to the above oral administration It may be given.
- the components (extracts of different mushrooms, etc.) necessary as a health food or a functional food are also included with reference to the above-mentioned oral administration preparation.
- edible or nutrient components used as foods and drinks can be appropriately added and used.
- the ultrafine particles can be contained in an amount of preferably about 0.01 to 80% by weight, more preferably about 0.05 to 20% by weight in terms of total sugar.
- seasonings and sweeteners that can be used as foods and drinks, and can be used in the form of drinks as solutions, tablets, granules, capsules, jelly types, ice cream types, frozen forms, etc. Can also be used.
- This food / drink is required for prophylaxis as well as healthy people, as well as those with various diseases, from severely to mildly ill patients, especially those with immune dysfunction, who are required to have systemic immune activation or immune regulation.
- the present invention can be applied to animals other than humans in the form of feed, pharmaceuticals, pharmaceutical compositions, and the like.
- the present invention resides in an aqueous solution in which an ultrafine particle of a component selected from a mushroom-derived component and 3-glucan is dispersed. From the description of the method of producing the ultrafine particle and various uses thereof, Can be easily understood and implemented. As a matter of course, this composition can be used for the above-mentioned various uses, particularly for pharmaceutical compositions and foods and drinks, similarly to the case of the ultrafine particles, and the description can be applied to the present invention. it can.
- the present invention provides, as another form, an immunostimulatory method or an immunoregulatory method characterized by ingesting or administering the ultrafine particles of the present invention into a living body.
- any of the above description of immunostimulants or immunomodulators furthermore, antitumor agents, antiinfective agents, antiviral agents, antiautoimmune agents, antidiabetic agents, antiallergic agents And anti-digestive disorders (therapeutic agents for irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), constipation, diarrhea, etc.) and the above for pharmaceutical compositions, foods and drinks, etc.
- the present invention can be easily implemented based on the description or preferred embodiments (examples) described later, and by referring to conventionally known techniques as necessary.
- the present invention can be used not only for humans but also for other animals as described above.
- animals cattle, pigs, sheep, horses, birds, etc.
- livestock industry pets, etc.
- fishes in the aquaculture industry (teleostichthys, crustaceans, etc.), or as an additive to be added to the feed, or as a pharmaceutical or pharmaceutical composition.
- Shiitake (raw Shiitake equivalent) Add about 4 L of water per 1 kg, crush using a colloid mill or the like (liquid volume after crushing: about 6 L), and heat to 95 ° C under reflux so that water does not evaporate by reflux etc. The mixture was boiled for 15 hours, and the obtained extract was filtered. The filtrate was concentrated under reduced pressure at 60 ° C to obtain about 1 L of a concentrate. The sugar was analyzed by the phenol-sulfuric acid method to obtain an extraction extract having a sugar content of 20 mg / ml (also referred to as "Shitatake extract”; also referred to as "Shitatake extract”). (Emulsifier treatment of Shiitake extract extract [micellarization])
- Lecithin (SLP-PC70) manufactured by Tsuruichi Lecithin Industry Co., Ltd. was added to deionized water to prepare a lecithin solution having the same concentration as the total sugar concentration of the shiitake extract. Next, to the lecithin solution, add the same amount of Shiitake extract, The mixture was stirred under vacuum (vacuum degree: 60 cm Hg, rotation speed of anchor mixer: 50 rpm, rotation speed of homomixer: 15,000 rpm) by Adehomo Mixer 2M-2 manufactured by Co., Ltd. Was prepared.
- the obtained pre-emulsified liquid is subjected to high-pressure emulsification (emulsification pressure: 1,500 kgf / cm 2 ) using a high-pressure emulsifier HI 1 type handle, two-stage type, manufactured by Sanwa Machine Co., Ltd., and a median diameter of about 100 nm.
- the extract of Shiitake mushroom extract (micellized Shiitake extract: product of the present invention) was produced.
- the median diameter was measured by LA-910 particle size distribution analyzer manufactured by Horiba, Ltd. using a laser diffraction / confusion type particle size distribution measuring method.
- Figure 1 shows the particle size distribution measurement results of Shiitake mushroom extract and micellar Shiiyake extract.
- the components in the mushroom extract showed a median particle diameter of about 120 m, and this was treated with an emulsifier ([micellarization]) to reduce the median particle diameter to about 0.09 m. Indicates that it was possible.
- 3-Glucan was purified from raw shiitake mushrooms by the method of Chihara et al. (Cancer Res., 3_0, 2776 (1970)). That is, j3-glucan is obtained by hot-water extraction of the raw fruit body of raw shiga, followed by ethanol fraction precipitation, and cetyltrimethylammonium hydroxoxide. A white powder was obtained by fractionation and precipitation with acetic acid, fractionation and elution with acetic acid, fractionation and elution with sodium hydroxide, and repeated removal of protein. The obtained white powder is suspended in distilled water, homogenized, and then subjected to high-temperature and high-pressure treatment in an autoclave.
- Lecithin (SLP-PC70) manufactured by Tsuruichi Lecithin Industry Co., Ltd. was added to deionized water to prepare a 8 mg Zm 1 concentration lecithin solution. Next, the same amount of the above-mentioned / 3-glucan solution was added to the lecithin solution, and high-pressure emulsification treatment (emulsification pressure of 1,500 kg) was performed using a two-stage high pressure emulsifier HI 1 handle manufactured by Sanwa Kikai Co., Ltd. f / cm 2 ) to produce a] 3-glucan micellized solution (micelleized] 3-Dalcan: product of the present invention) having a median diameter of about 100 nm.
- FIG. 2 shows the measurement results of the particle size distributions of the ⁇ -glucan solution and the micellized ⁇ -glucan.
- the 3-glucan in the] 3-glucan solution has formed aggregates, and has a median particle diameter of about 120 m, which can be treated with an emulsifier ([micellarization]). , Indicating that the median particle diameter could be reduced to about 0.09 m
- Sarcoma 180 tumor cells which were passaged by intraperitoneal transplantation into ICR mice (female, 4 weeks old), were collected in the form of ascites fluid, and brought to 3 ⁇ 10 Vm 1 with saline. Prepared. This diluted cell solution was implanted subcutaneously into the right lumbar dorsum of an ICR mouse (female, 4 weeks old) with a 25 G needle using 0.1 lmZmou se.
- micellar extract of shiitake extract micellar extract of shiitake extract
- the administration was oral once a day, with a total of 10 administrations in 5 doses and 2 rests.
- the dose per dose the dose of 1 mgZm1 was added to the 1 mg / kg administration group in terms of total sugar, and 0.2 ml Zmouse was applied to the 100 mg / Zkg use group in terms of total sugar.
- micellar shiitake extract The numbers in parentheses after the shiitake extract and the micellar shiitake extract shown in the column of the administration group in Tables 1 and 2 are doses in terms of total sugar amount, and the unit is mgZkg. In the examples, those subjected to ultrafine particle treatment using an emulsifier are referred to as miscellular shiitake extract.
- Tumor size and body weight were measured once a week.
- the tumor weight was calculated from the tumor diameter using the following formula.
- Tumor weight (mg) tumor minor axis (mm) 2 X tumor major axis (mm) ⁇ 2
- Host weight was also calculated from tumor weight and body weight.
- Host weight (g) body weight (g) — tumor weight (g) The tumor growth inhibition rate was calculated from the tumor weight.
- Tumor growth inhibition rate (%) (1 tumor weight in one administration group ⁇ ⁇ tumor weight in untreated group) X I 0 0
- micellar Xyuga extract The efficacy of this model was evaluated based on the tumor growth inhibition rate in each week and the number of tumor survivors 35 days after tumor implantation.
- Tables 1 and 2 show the results of the tumor growth inhibitory effect of micellar Xyuga extract.
- t-test Student'st -test: In each group, t-test was performed on the untreated group.
- mice treated with micellar shiitake extract tumor growth was gradually suppressed during the administration period compared to the untreated group, and on Day 16 (two days after the end of administration), In the oral administration group of 1 OmgZkg in terms of the total sugar content of micellarized Shiyuka extract, the tumor growth was significantly suppressed at p ⁇ 0.01, with p ⁇ 0.01.
- mice Micellar shiitake extract (100) 28.8 Days after tumor transplantation 16 days As is clear from the above results, it was confirmed that the ultrafine particles of the product of the present invention exhibited the desired drug effect as compared with the conventional product. .
- the i3_glucan purified in (Example 2) was dissolved in sodium hydroxide solution (1 ⁇ 25), and methanol was precipitated. Repeated times, washed with methanol and acetone, and dried under reduced pressure (40, 15 hours) to obtain standard i3-glucan with nitrogen: 0.03% or less, ignition residue: 1.5% or less Was.
- 3-Glucan in shiitake mushroom extract was quantified by applying the method of Sasaki et al. (Gann, 67 (2) 191-5 (1976)) and using previously purified standard) 3-glucan. That is, Shiitake mushroom extract and standard 0-glucan were prepared in sodium hydroxide solution (2 g / d 1), respectively, and the Congo red solution (1 OmgZd 1) and phosphoric acid (2.5 g / d 1) were added. The absorbance at 535 nm was quantified by measuring the absorbance at 535 nm using a shift of the maximum absorption wavelength of Congo Red caused by 1,3-glucan.
- micellarized Shitake mushroom extract (lecithin concentration 0) so that the concentration of 3-glucan was 0.2 mgZm1. .8 mg Zml) was prepared.
- a / 3-glucan solution was emulsified with lecithin to a concentration of 0.2 mg / ml to obtain a micellized 13-glucan solution.
- micellar ⁇ -glucan Tumor growth inhibitory effect of micellar ⁇ -glucan
- micellarized Shiyuuga extract, micellarized] 8-glucan and] 3-glucan solution prepared above was examined in the same manner as in Example 3 above. That is, Sarcoma 180 tumor cells, which have been passaged by intraperitoneal transplantation into ICR mice (female, 4 weeks old), are collected in the form of ascites and adjusted to 3 ⁇ 10 Vm 1 with physiological saline. did. This diluted cell solution was implanted subcutaneously into the right lumbar dorsum of an ICR mouse (female, 4 weeks old) with 0.1 lm 1 Zmouse using a 25 G injection needle.
- micellar shiitake kiss micellar / 3-glucan and / 3-glucan was started.
- the administration was oral once a day, with 5 administrations and 2 rests, for a total of 10 administrations.
- the group administered with lmgZkg in terms of / 3-glucan was administered with a solution prepared at a concentration of 0.2mgZm1 at a concentration of / 3-glucan at 0.1ml / mouse.
- micellarized Shiyuka extract and micellized 3-glucan and) 3-glucan shown in the column of administration group in Tables 3 and 4 are the doses in terms of / 3-glucan conversion. Yes, the unit is mgZkg.
- micellarized Shiyuga extract and micellarized / 3-Dalkan are referred to as micellarized Shiyuga extract and micellarized / 3-Dalkan.
- t-test Student's st-test: t-test was performed for each group with respect to the untreated group.
- mice treated with micellar sieve extract and micelles 3-glucan, that is, those treated with ultrafine particles
- the tumor growth was gradually suppressed during the treatment period compared to the untreated group. (2 days after the end of administration), in the oral administration group of j8-glucan in terms of the amount of 1 mg Zkg, the tumor growth was significantly suppressed to 0.01 (p-0.01).
- the ultrafine particles (micellar shiitakekis and micellarized) 3-glucan of the product of the present invention are more objective than the conventional product () 3-glucan solution). It was confirmed that the drug was effective.
- micellar shiitake extract In order to investigate the activation of intestinal mucosal immunity by the micellar shiitake extract, the same method as in Example 3 was used. In other words, Sarcoma 180 tumor cells, which have been passaged by intraperitoneal transplantation into ICR mice (female, 4 weeks old), are collected in the form of ascites, and adjusted to 3 ⁇ 10 Vm 1 with saline. did. This diluted cell solution was implanted subcutaneously into the right lumbar dorsum of an ICR mouse (female, 4 weeks old) at 0.1 ml / mouse using a 25G injection needle.
- micellar sieve Administration of Yuga extract was started. Dosing once daily Oral administration was performed, with 5 injections and 2 rests, for a total of 10 injections.
- the emulsifier used was lecithin 2 mg / m1 at a concentration of 0.1 ml / mouse, and the emulsifier added with Shiyuga extract extract] 3-glucan equivalent 1 mg Z kg
- a ⁇ -glucan concentration of 0.2 mg Zml (lecithin concentration: 2.Omg / m 1) was administered at a dose of 0.1 lm 1 / mouse
- micellarized Shiyuga extract was / 3 -In terms of glucan equivalent lmgZkg
- the dosing solution prepared at 0.2mgZml ⁇ -glucan concentration (lecithin concentration 2mg / ml) was administered with 0.1m1 Zmouse, / 3g glucan
- the group administered with a reduced amount of 3 mgZkg was administered with 0.3 ml 1 "mouse.
- mice On the 2nd day after administration, small intestine with Peyer's patch was excised from each group and normal mice (3 mice), fixed in 10% formalin, embedded in paraffin, prepared paraffin sections, and deparaffinized, followed by matoxylin and eosin staining. The accumulation of mononuclear cells (immune cells) in the lamina intestinal mucosa was observed under a microscope.
- the numbers in parentheses after the extract of Shiitake mushroom extract and the extract of micellarized Shiitake extract shown in the column of administration group in Table 5 are the dose in terms of ⁇ -glucan, and the unit is mg / kg. Further, in the examples, those subjected to ultrafine particle treatment using an emulsifier are referred to as myelinated Shiyuga extract.
- the number of villi was measured with a microscope (100 to 300 cells / sample), the number of mononuclear cells accumulated in the lamina propria was measured, and the ratio (%) of the accumulated image per villi was calculated.
- t-test Student'st -test: t-test was performed for each group with respect to the untreated group.
- mice no significant difference
- p ⁇ 0.1 significant tendency
- p ⁇ 0.01 significant difference
- mice untreated group with cancer, emulsifier (lecithin 1 OmgZkg oral administration group)
- Treatment group shiitake extract as emulsifier
- Microscopic observation of the pathological tissue of the small intestine in the oral administration group of lmg / kg in terms of 3-glucan and 1 mgkg and 3 mgkg in terms of micelle-modified Shitake mushroom extract ⁇ -glucan in terms of 3-glucan resulted in micellization.
- the intestinal mucosa intrinsic phase showed a significant tendency in the small intestinal mucosa (p 0.1) compared with the untreated group.
- micellar shiitake extract induces (activates) an immune reaction in the intestinal mucosa.
- delayed hypersensitivity reactions were evaluated. The method for evaluating delayed type hypersensitivity reaction will be described.
- Tumor transplantation was performed in the same manner as in Example 3 above. That is, Sarcoma 180 tumor cells, which had been passaged by intraperitoneal transplantation into ICR mice (female, 4 weeks old), were collected in the form of ascites and adjusted to 3 ⁇ 10 1 with physiological saline. . The cell dilution was implanted subcutaneously into the right lumbar dorsum of an ICR mouse (female, 4-week-old) with a 0.1 G lzmouse using a 25G injection needle.
- micellar shiitake kiss micellarized / 3-glucan
- 3-glucan solution was started.
- the administration was oral once a day, and was performed 9 times in 5 doses and 2 rests.
- the micellar shiitake extract and micellar ⁇ -glucan were administered in a dose of 1 mg / kg in terms of 3-glucan at a dose of 0.2 mgZml ( ⁇ -glucan concentration: 0.8 mgZm 1).
- the dose was 1 m 1 Zmo use.
- the ⁇ -glucan solution was administered to a group administered with a ⁇ -glucan amount of 1 mg kg at a ⁇ -glucan concentration of 0.2 mgZm 1 at 0.1 ml Zmouse.
- micellarized shiitake extract-administered group micellized
- Delayed type hypersensitivity reaction (DTH: De 1 ay ed Type Hypersensitivity) was performed using 7 mice each of 3-glucan administration group and ⁇ -glucan solution administration group and 3 normal mice. ) Tested. That is, on the 9th day after tumor transplantation (8 days after the start of administration), as a control, 50 ⁇ l of physiological saline was added to the right foot ad and Sarc 0111 & 180 cells were solubilized in the left footpad by 31 KC1 solubilization method.
- the tumor antigen solution obtained by the freeze-thaw method (5 x 1 (treated with a cell suspension of TZm1)) was administered with 501, and the thickness of the right and left feet was measured 24 hours later. The swelling was calculated and the DTH response was tested.
- Foot swelling (mm) left foot thickness (mm) — right foot thickness (mm)
- micellarized Shiyuga extract micellarized
- micellarized Shiyuga extract micellarized / 3-glucan.
- t-test Student'st-test: t-test was performed for each group with respect to the untreated group.
- micellar shiitake extract and micellarized / 3-glucan can elicit a systemic immune response to tumor antigens.
- micellarized Shiyuga extract In order to examine the antiallergic effect of micellarized Shiyuga extract, NC mice, a mouse model of atopic dermatitis, were examined. That is, an antigen prepared in ethanol and acetone (4: 1) was added to 20 8-week-old male NC mice at abdomen and feet by picryl chloride (5% (w / v)) 1501 / mouse. Sensitization, 4 days after sensitization, once a week for 6 weeks in olive oil for 6 weeks. Induction antigen: picryl chloride (0.8% (w / v)) at 1501 / mouse It was applied to the back and both ears (both inside and outside). The administration was started once a day from the day before the antigen sensitization for 46 days.
- picryl chloride 5% (w / v)
- micellarized Shiyuka extract was orally administered at 0.1 ml Ouse in a solution prepared to be 0.1 SmgZm1 in terms of ⁇ -glucan. This dose is equivalent to the dose of lmgZkg in terms of 3-glucan in a single dose.
- Anti-allergic effect is determined by antigen sensitization once a week, weight measurement, degree of dermatitis onset; ema), 4 abrasion, tissue defect (excoriation / erosion), 5 scab formation, scarring / dryness were observed and scored (score: 0; asymptomatic, 1; mild, 2; Moderate, 3; altitude). Further, after the antigen sensitization, fundus examination was performed on the 29th and 46th days. Serum was collected, and the amount of immunoglobulin E (IgE) in the serum was measured by ELISA.
- IgE immunoglobulin E
- mice On day 46 after sensitization, the amount of IgE was 5.0 gZm1 or more in all 10 mice in the control group, while the amount of IgE in the mice treated with micellarized Shiyuka extract was more than 5.0 gZm1. Only 4 grew to 5.0 gZm 1 or more, and the remaining 6 grew to less than 5.0 g / ml, and the increase in IgE was significantly suppressed (Fisher probability test: P ⁇ 0. 05).
- mice in the control group showed a total dermatitis score of 9 or more, whereas the mice treated with micellarized Shiyuka extract In 5 of the 10 animals, the sum of dermatitis scores was 9 or more, and the remaining 5 animals had a dermatitis score of less than 9, indicating that dermatitis was suppressed compared to the control group. .
- micellized Shiyuka extract In order to examine the effect of micellized Shiyuka extract on diabetes, the effect on blood glucose elevation was examined using dbZdb mice, which are type II diabetes model mice.
- a 5-week-old male dbZdb mouse was divided into two groups, each group consisting of 9 mice, one of which was a control group that had free access to water until the age of 12 weeks, and the other was a mice group until the age of 12 weeks. He was given free drinking water.
- the concentration of the micellarized Shiyuka extract was 0.1 OlmgZml (the lecithin concentration was 0.1mgZml) in terms of j8-glucan. Water intake was measured weekly to calculate the oral intake of j6-glucan.
- the effect was determined by collecting blood from the fundus every week, measuring the blood sugar level, and examining the effect of suppressing the increase in blood sugar level.
- the oral intake of 3-glucan was 0.15 mg / mou se / day to 0.36 mg / mou s ez d ay at 6 to 12 weeks of age.
- the blood glucose level of the control group was 504.11 ⁇ 50.0 SmgZd 1
- the blood glucose level of the micellized shiitake extract administration group was 406.22 ⁇ 75.5 SmgZd 1
- the rise in blood glucose was significantly suppressed ( S tudent 'st—test: p ⁇ 0.01).
- immunostimulants and immunomodulators capable of improving the immune status of animals, especially humans, and especially pharmaceutical compositions and foods and drinks having such excellent immunostimulatory and immunomodulatory activities ( Health foods, functional foods, etc.). Furthermore, novel substances (or new compositions) that can be used as active ingredients of such excellent products, in particular, ultrafine particles of components selected from mushroom-derived components and / 3-glucan, such as mushrooms It is also possible to provide a microparticulate extract, preferably a water extract, which is treated with a dispersant (dispersed product), particularly a micellar solution obtained by treating the extract with an emulsifier.
- an immunostimulatory method or an immunomodulatory method for treating or preventing various diseases the use of the ultrafine particles as the immunostimulant or the immunomodulator, or the use of the ultrafine particles Antineoplastic, Antiinfective, Antiviral, Antiautoimmune, Antidiabetic, Antiallergic, Antidigestive (Irritable bowel syndrome (IBS), Inflammatory bowel disease (IBD), Constipation , Therapeutic agents for diarrhea, etc.), etc., and also for use in the manufacture of pharmaceuticals.
- a mushroom-derived component or a medicinal component of / 3-glucan particularly an ultrafine particle of the active ingredient having the immunostimulating action and / or immunomodulating action (or And the method is also provided.
- pharmaceutical compositions, foods and drinks (healthy foods, functional foods, etc.) utilizing the active ingredient can be industrially and simply provided.
- the present invention is extremely useful industrially, particularly in many fields such as medicine, pharmaceuticals, and foods.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Endocrinology (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02722816A EP1389466B1 (en) | 2001-04-27 | 2002-04-26 | A dispersion on the basis of beta-glucan containing superfine particles, a corresponding process of manufacturing and the use of said dispersion |
JP2002584947A JP3633601B2 (ja) | 2001-04-27 | 2002-04-26 | 免疫賦活剤 |
KR10-2003-7013999A KR20040039195A (ko) | 2001-04-27 | 2002-04-26 | 면역강화제 |
DE60218299T DE60218299T2 (de) | 2001-04-27 | 2002-04-26 | Eine Dispersion aus Beta-Glukan enthaltenden hochfeinen Partikel, ein entsprechender Herstellungsprozess und die Verwendung der Dispersion |
US10/692,684 US20040142000A1 (en) | 2001-04-27 | 2003-10-27 | Immune activator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001132513 | 2001-04-27 | ||
JP2001-132513 | 2001-04-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/692,684 Continuation US20040142000A1 (en) | 2001-04-27 | 2003-10-27 | Immune activator |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002087603A1 true WO2002087603A1 (fr) | 2002-11-07 |
Family
ID=18980516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004205 WO2002087603A1 (fr) | 2001-04-27 | 2002-04-26 | Immunostimulants |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040142000A1 (ja) |
EP (1) | EP1389466B1 (ja) |
JP (1) | JP3633601B2 (ja) |
KR (3) | KR20090057480A (ja) |
CN (1) | CN100391439C (ja) |
AT (1) | ATE354355T1 (ja) |
DE (1) | DE60218299T2 (ja) |
TW (1) | TWI300714B (ja) |
WO (1) | WO2002087603A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005029977A1 (en) * | 2003-10-02 | 2005-04-07 | Yong Dal Shin | Beverage and food which contain the extract of fomes fomentarius |
JP2005272405A (ja) * | 2004-03-26 | 2005-10-06 | Hokuto Corp | 皮膚機能改善剤及び皮膚機能改善食品 |
WO2005095412A1 (ja) * | 2004-04-01 | 2005-10-13 | Kureha Corporation | 抗アレルギー剤 |
JP2006111820A (ja) * | 2004-10-18 | 2006-04-27 | Ajinomoto Co Inc | シイタケ子実体からのβ−グルカンの製造方法 |
JP2006115833A (ja) * | 2004-09-24 | 2006-05-11 | Katsumi Koide | 茸類の菌糸体加工方法 |
WO2006137122A1 (ja) | 2005-06-20 | 2006-12-28 | Michio Tani | 抗エイズ剤 |
JP2007501829A (ja) * | 2003-08-11 | 2007-02-01 | ルサフル、エ、コンパニ | 高血糖症の治療もしくは予防、または血糖の安定化に用いられる酵母細胞壁 |
JP2007204717A (ja) * | 2006-02-06 | 2007-08-16 | Nagaoka Univ Of Technology | きのこ由来の多糖類取得方法 |
JP2008509933A (ja) * | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
WO2009116507A1 (ja) * | 2008-03-18 | 2009-09-24 | 株式会社アミノアップ化学 | 経腸栄養剤 |
JP2010100576A (ja) * | 2008-10-24 | 2010-05-06 | Unitika Ltd | 便秘改善剤 |
US20100216743A1 (en) * | 2003-07-16 | 2010-08-26 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US8758768B2 (en) | 2001-09-03 | 2014-06-24 | Glycanova As | Process for production of fungal extracellular immune stimulating compounds |
US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
WO2018062343A1 (ja) * | 2016-09-30 | 2018-04-05 | 合同会社レビアスファーマ | 粒子およびその製造方法 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906492B2 (en) * | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
KR100775133B1 (ko) * | 2005-04-06 | 2007-11-09 | 주식회사 한립생명공학 | 베타글루칸과 버섯 균사체 추출물을 혼합하여 제조한 항균 또는 항진균 제제의 제조방법 및 상기 제제를 함유하는 손발청결보습제 |
WO2006119774A1 (en) * | 2005-05-13 | 2006-11-16 | Medimush As | Feed or food products comprising fungal material |
KR100734898B1 (ko) * | 2005-10-28 | 2007-07-03 | 주식회사 글루칸 | 베타-글루칸을 유효성분으로 포함하는 신장질환 치료용 약학적 조성물 |
US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US9095603B2 (en) | 2006-04-05 | 2015-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-allergy compositions |
US20110129548A1 (en) * | 2006-10-20 | 2011-06-02 | Bioagra, Llc | Immunopotentiating Compositions Comprising Beta-1, 3/1, 6-D-Glucan and Uses Thereof |
WO2008057253A2 (en) | 2006-10-27 | 2008-05-15 | Bioresponse, L.L.C. | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
FR2918988B1 (fr) * | 2007-07-20 | 2010-12-24 | Caster | Extrait polysaccharidique de lentinus et compositions pharmaceutiques, cosmetiques ou nutraceutiques comprenant un tel extrait. |
JP2011503161A (ja) * | 2007-11-13 | 2011-01-27 | バイオテック・ファルマコン・アーエスアー | 腸管の炎症性疾患を処置または予防する方法 |
WO2009100331A2 (en) * | 2008-02-06 | 2009-08-13 | The Procter & Gamble Company | Compositions methods and kits for enhancing immune response to a respiratory condition |
CN101569414B (zh) * | 2008-04-29 | 2013-04-10 | 安琪酵母股份有限公司 | 一种富含酵母硒和酵母葡聚糖的组合物 |
CN102132864A (zh) * | 2011-02-22 | 2011-07-27 | 江苏安惠生物科技有限公司 | 诱导益生菌增殖的纳米食药用菌纤维及生产方法 |
KR20140128004A (ko) * | 2013-04-26 | 2014-11-05 | 한명순 | 송아지 설사 예방 및 개선용 조성물 및 그 제조방법 |
CN103272215A (zh) * | 2013-05-30 | 2013-09-04 | 北京市农林科学院 | 红平菇蛋白质提取物及其抗肿瘤的应用 |
CN103272214A (zh) * | 2013-05-30 | 2013-09-04 | 北京市农林科学院 | 金针菇蛋白质提取物及其抗肿瘤的应用 |
LT3102185T (lt) | 2014-02-03 | 2022-01-10 | Apurano Pharmaceuticals Gmbh | Gamtinių medžiagų nanosuspensija ir jos paruošimo būdas |
CN115153023B (zh) * | 2014-07-02 | 2024-06-04 | 嘉康利公司 | 用于增强免疫的组合物和方法 |
US10092609B2 (en) | 2015-01-16 | 2018-10-09 | James A. Wieser | Process for preparing medicinal mycological preparations |
KR101695186B1 (ko) * | 2016-02-05 | 2017-01-11 | 원광대학교산학협력단 | 당뇨병 예방, 개선 또는 치료용 조성물 |
CN106072533A (zh) * | 2016-06-18 | 2016-11-09 | 江苏阜丰生物科技有限公司 | 一种供糖尿病患者食用的全营养配方食品 |
CN106333969A (zh) * | 2016-08-30 | 2017-01-18 | 青海民族大学 | 圆孢蘑菇抑制hdac1酶有效部位及制法和应用 |
CN106309511A (zh) * | 2016-08-30 | 2017-01-11 | 青海民族大学 | 圆孢蘑菇抑制cdc25酶有效部位及制法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987001037A1 (en) * | 1985-08-19 | 1987-02-26 | The Administrators Of The Tulane Educational Fund | Soluble phosphorylated glucan |
WO1996028476A1 (en) * | 1995-03-13 | 1996-09-19 | Novogen Research Ltd. | Process for glucan preparation and therapeutic uses of glucan |
WO1997001330A1 (en) * | 1995-06-26 | 1997-01-16 | Research Triangle Pharmaceuticals | Novel adjuvant compositions and vaccine formulations comprising same |
WO2000003724A1 (fr) * | 1998-07-16 | 2000-01-27 | Hayashi, Akira | Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif |
JP2001112436A (ja) * | 1999-10-15 | 2001-04-24 | Oji Paper Co Ltd | 担子菌を含有する健康食品、飼料ならびにペットフード |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1356449A (en) * | 1970-12-30 | 1974-06-12 | Iizuka C | Process for extracting water soluble components of the hyphae of edible fungi |
DE3019614A1 (de) * | 1980-05-22 | 1981-12-03 | Sankyo Co., Ltd., Tokyo | Hydrolysiertes polysaccharid |
US5032401A (en) * | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
EP0490995A1 (en) * | 1989-09-08 | 1992-06-24 | Alpha Beta Technology | Method for producing soluble glucans |
CN1030038C (zh) * | 1991-03-07 | 1995-10-18 | 中国科学院石家庄农业现代化研究厅 | 以胡萝卜为药剂辅料的药剂制备方法 |
JPH11262370A (ja) * | 1998-03-18 | 1999-09-28 | Nippon Shokukin Kogyo Kk | 健康食品素材としてのハラタケ科キノコの処理法および健康食品 |
US6616928B1 (en) * | 1998-10-20 | 2003-09-09 | Yukiguni Maitake Co., Ltd. | Active oxygen scavenger and cancer chemopreventer from Grifola |
JP2000159682A (ja) * | 1998-09-17 | 2000-06-13 | Kozo Niwa | 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法 |
DE19911058B4 (de) * | 1999-03-12 | 2004-09-30 | Biotec Asa | Verwendung von nanoskaligen wasserlöslichen β-(1,3)-Glucanen |
EP1414865B1 (en) * | 2000-08-03 | 2014-04-09 | Abac R & D Ag | Isolation of glucan particles and uses thereof |
EP1409000A1 (en) * | 2000-08-18 | 2004-04-21 | Atlas World USA, Inc. | Use of agaricus blazei murill to prevent or treat skin and other disorders |
US6645502B2 (en) * | 2001-09-17 | 2003-11-11 | Revlon Consumer Products Corporation | Anhydrous cosmetic compositions containing mushroom extract |
WO2004014320A2 (en) * | 2002-08-13 | 2004-02-19 | Biopolymer Engineering, Inc. | Methods of using beta glucan as a radioprotective agent |
-
2002
- 2002-04-26 WO PCT/JP2002/004205 patent/WO2002087603A1/ja active Application Filing
- 2002-04-26 KR KR1020097010648A patent/KR20090057480A/ko not_active Application Discontinuation
- 2002-04-26 AT AT02722816T patent/ATE354355T1/de not_active IP Right Cessation
- 2002-04-26 CN CNB028089561A patent/CN100391439C/zh not_active Expired - Fee Related
- 2002-04-26 EP EP02722816A patent/EP1389466B1/en not_active Expired - Lifetime
- 2002-04-26 KR KR1020107022055A patent/KR20100112205A/ko not_active Application Discontinuation
- 2002-04-26 JP JP2002584947A patent/JP3633601B2/ja not_active Expired - Lifetime
- 2002-04-26 KR KR10-2003-7013999A patent/KR20040039195A/ko not_active Application Discontinuation
- 2002-04-26 TW TW091108765A patent/TWI300714B/zh not_active IP Right Cessation
- 2002-04-26 DE DE60218299T patent/DE60218299T2/de not_active Expired - Lifetime
-
2003
- 2003-10-27 US US10/692,684 patent/US20040142000A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987001037A1 (en) * | 1985-08-19 | 1987-02-26 | The Administrators Of The Tulane Educational Fund | Soluble phosphorylated glucan |
WO1996028476A1 (en) * | 1995-03-13 | 1996-09-19 | Novogen Research Ltd. | Process for glucan preparation and therapeutic uses of glucan |
WO1997001330A1 (en) * | 1995-06-26 | 1997-01-16 | Research Triangle Pharmaceuticals | Novel adjuvant compositions and vaccine formulations comprising same |
WO2000003724A1 (fr) * | 1998-07-16 | 2000-01-27 | Hayashi, Akira | Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif |
JP2001112436A (ja) * | 1999-10-15 | 2001-04-24 | Oji Paper Co Ltd | 担子菌を含有する健康食品、飼料ならびにペットフード |
Non-Patent Citations (1)
Title |
---|
ARTURSSON P. ET AL.: "Macrophage stimulation with some structurally related polysaccharides", SCAND. J. IMMUNOL., vol. 25, no. 3, 1987, pages 245 - 254, XP002955616 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10471135B2 (en) | 2001-09-03 | 2019-11-12 | Glycanova As | Production of fungal extracellular immune stimulating compounds |
US8758768B2 (en) | 2001-09-03 | 2014-06-24 | Glycanova As | Process for production of fungal extracellular immune stimulating compounds |
US9249438B2 (en) | 2001-09-03 | 2016-02-02 | Glycanova As | Production of fungal extracellular immune stimulating compounds |
US20100216743A1 (en) * | 2003-07-16 | 2010-08-26 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
JP2007501829A (ja) * | 2003-08-11 | 2007-02-01 | ルサフル、エ、コンパニ | 高血糖症の治療もしくは予防、または血糖の安定化に用いられる酵母細胞壁 |
JP4808619B2 (ja) * | 2003-08-11 | 2011-11-02 | ルサフル、エ、コンパニ | 高血糖症の治療もしくは予防、または血糖の安定化に用いられる酵母細胞壁 |
WO2005029977A1 (en) * | 2003-10-02 | 2005-04-07 | Yong Dal Shin | Beverage and food which contain the extract of fomes fomentarius |
JP2005272405A (ja) * | 2004-03-26 | 2005-10-06 | Hokuto Corp | 皮膚機能改善剤及び皮膚機能改善食品 |
WO2005095412A1 (ja) * | 2004-04-01 | 2005-10-13 | Kureha Corporation | 抗アレルギー剤 |
JP2008509933A (ja) * | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
JP2006115833A (ja) * | 2004-09-24 | 2006-05-11 | Katsumi Koide | 茸類の菌糸体加工方法 |
JP4560145B2 (ja) * | 2004-09-24 | 2010-10-13 | 株式会社 アンフィニ | 茸類の菌糸体加工方法 |
JP2006111820A (ja) * | 2004-10-18 | 2006-04-27 | Ajinomoto Co Inc | シイタケ子実体からのβ−グルカンの製造方法 |
US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
WO2006137122A1 (ja) | 2005-06-20 | 2006-12-28 | Michio Tani | 抗エイズ剤 |
US7638146B2 (en) | 2005-06-20 | 2009-12-29 | Michio Tani | Anti-AIDS drug |
JP2007204717A (ja) * | 2006-02-06 | 2007-08-16 | Nagaoka Univ Of Technology | きのこ由来の多糖類取得方法 |
JPWO2009116507A1 (ja) * | 2008-03-18 | 2011-07-21 | 株式会社アミノアップ化学 | 経腸栄養剤 |
WO2009116507A1 (ja) * | 2008-03-18 | 2009-09-24 | 株式会社アミノアップ化学 | 経腸栄養剤 |
JP2010100576A (ja) * | 2008-10-24 | 2010-05-06 | Unitika Ltd | 便秘改善剤 |
WO2018062343A1 (ja) * | 2016-09-30 | 2018-04-05 | 合同会社レビアスファーマ | 粒子およびその製造方法 |
JPWO2018062343A1 (ja) * | 2016-09-30 | 2019-07-25 | 合同会社レビアスファーマ | 粒子およびその製造方法 |
JP7274863B2 (ja) | 2016-09-30 | 2023-05-17 | 合同会社レビアスファーマ | 粒子およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP3633601B2 (ja) | 2005-03-30 |
CN1505524A (zh) | 2004-06-16 |
TWI300714B (en) | 2008-09-11 |
ATE354355T1 (de) | 2007-03-15 |
DE60218299D1 (de) | 2007-04-05 |
DE60218299T2 (de) | 2007-10-31 |
KR20090057480A (ko) | 2009-06-05 |
KR20040039195A (ko) | 2004-05-10 |
EP1389466A1 (en) | 2004-02-18 |
KR20100112205A (ko) | 2010-10-18 |
EP1389466B1 (en) | 2007-02-21 |
US20040142000A1 (en) | 2004-07-22 |
JPWO2002087603A1 (ja) | 2004-08-12 |
EP1389466A4 (en) | 2004-09-22 |
CN100391439C (zh) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002087603A1 (fr) | Immunostimulants | |
US20060159698A1 (en) | Drug product for intestinal disease | |
Namba | Maitake D-fraction: healing and preventive potential for cancer | |
US10092609B2 (en) | Process for preparing medicinal mycological preparations | |
TWI386485B (zh) | 瓦茸菌株(Tramete Versicolor)及其萃取物,以及其用途 | |
KR101613693B1 (ko) | 괭생이 모자반 추출물을 유효성분으로 포함하는 아토피성 피부질환 예방 또는 치료용 조성물 및 이의 제조방법 | |
Cristine da Silva de Souza et al. | Agaricus blazei bioactive compounds and their effects on human health: benefits and controversies | |
WO2006093267A1 (ja) | 免疫調節作用を有する発酵組成物 | |
JP2002080364A (ja) | 免疫増強組成物 | |
JP5337535B2 (ja) | Nk活性増強剤 | |
KR102568433B1 (ko) | 사이클로덱스트린-커큐민 캡슐화된 키토산/알지네이트 경구용 나노입자 및 이의 대장염 치료 용도 | |
JP4752233B2 (ja) | 免疫賦活剤 | |
JP2004315512A (ja) | 機能性組成物 | |
JP3662248B2 (ja) | 免疫賦活剤 | |
WO2006082649A1 (ja) | 多嚢胞性卵巣症候群(pcos)治療剤 | |
CN102379905B (zh) | 一种具有高效抗癌作用的含灵芝孢子油中药组合物 | |
JP2005068114A (ja) | タモギタケ子実体組成物及びその製造方法、並びに免疫賦活剤、抗癌剤及び食品製剤 | |
EP2570131A1 (en) | Formulation against leishmaniasis and use thereof | |
JP2005089388A (ja) | 免疫賦活作用増強剤 | |
CN1185319A (zh) | 肿瘤-血管生成抑制剂和药学组合物 | |
CN114532412B (zh) | 一种高效递送南瓜籽油功能活性的方法 | |
JP2005179315A (ja) | 免疫強化剤及びその製造方法 | |
JP2001097881A (ja) | マイタケ由来の発がん防止剤及び発がん防止用食品又は飼料 | |
JP2001322945A (ja) | ヒメマツタケ(アガリクス・ブラゼイ・ムリル)を有効成分として含有する抗高脂血症剤およびそれを含む抗高脂血症機能を持つ食品 | |
JP2003235510A (ja) | 担子菌フエリナス・バウミイ株の子実体衝撃粉砕下微粉末を使用する健康食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020037013999 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10692684 Country of ref document: US Ref document number: 028089561 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002722816 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002722816 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002722816 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097010648 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107022055 Country of ref document: KR |